"Cisplatin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle.
| Descriptor ID |
D002945
|
| MeSH Number(s) |
D01.210.375 D01.625.125 D01.710.100
|
| Concept/Terms |
Cisplatin- Cisplatin
- cis-Diamminedichloroplatinum(II)
- Platinum Diamminodichloride
- Diamminodichloride, Platinum
- cis-Platinum
- cis Platinum
- Dichlorodiammineplatinum
- cis-Diamminedichloroplatinum
- cis Diamminedichloroplatinum
- cis-Dichlorodiammineplatinum(II)
|
Below are MeSH descriptors whose meaning is more general than "Cisplatin".
Below are MeSH descriptors whose meaning is more specific than "Cisplatin".
This graph shows the total number of publications written about "Cisplatin" by people in this website by year, and whether "Cisplatin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 2 | 8 | 10 |
| 1997 | 1 | 8 | 9 |
| 1998 | 2 | 7 | 9 |
| 1999 | 1 | 5 | 6 |
| 2000 | 2 | 5 | 7 |
| 2001 | 1 | 8 | 9 |
| 2002 | 1 | 4 | 5 |
| 2003 | 2 | 4 | 6 |
| 2004 | 4 | 7 | 11 |
| 2005 | 5 | 10 | 15 |
| 2006 | 2 | 7 | 9 |
| 2007 | 1 | 6 | 7 |
| 2008 | 2 | 9 | 11 |
| 2009 | 2 | 7 | 9 |
| 2010 | 1 | 8 | 9 |
| 2011 | 1 | 12 | 13 |
| 2012 | 4 | 4 | 8 |
| 2013 | 2 | 6 | 8 |
| 2014 | 2 | 7 | 9 |
| 2015 | 2 | 4 | 6 |
| 2016 | 7 | 7 | 14 |
| 2017 | 3 | 6 | 9 |
| 2018 | 5 | 6 | 11 |
| 2019 | 5 | 5 | 10 |
| 2020 | 6 | 9 | 15 |
| 2021 | 5 | 5 | 10 |
| 2022 | 0 | 8 | 8 |
| 2023 | 1 | 6 | 7 |
| 2024 | 4 | 6 | 10 |
| 2025 | 3 | 5 | 8 |
| 2026 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cisplatin" by people in Profiles.
-
Consensus Molecular Subtypes Inform HIPEC Agent Selection in Colorectal Cancer Peritoneal Metastases. Ann Surg Oncol. 2026 Jul; 33(7):6140-6145.
-
Xevinapant or Placebo Plus Platinum-Based Chemoradiotherapy in Unresected Locally Advanced Squamous Cell Carcinoma of the Head and Neck (TrilynX): A Randomized, Phase III Study. J Clin Oncol. 2025 10 10; 43(29):3209-3220.
-
Impact of Population Pharmacogenomics on Cisplatin-Induced Neurotoxicities in Testicular Cancer Survivors. Cancer Med. 2025 Sep; 14(17):e71218.
-
Adverse event profiles and management of cisplatin-based chemoradiotherapy in locally advanced head and neck squamous cell carcinoma: a systematic review. Oral Oncol. 2025 Oct; 169:107596.
-
Real-World Single-Center Experience with Neoadjuvant Gemcitabine, Cisplatin, and Durvalumab in Borderline Resectable Cholangiocarcinoma. Ann Surg Oncol. 2025 Oct; 32(10):7228-7239.
-
Durvalumab Plus Platinum-Etoposide in Extensive-Stage Small-Cell Lung Cancer: Outcomes in Age, Sex, and Platinum Subgroups From the Phase 3 CASPIAN Study. Clin Lung Cancer. 2025 Dec; 26(8):626-641.
-
Conversion to Resection After Neoadjuvant Gemcitabine, Cisplatin, and Nab-Paclitaxel for Borderline Resectable CCA: A Real-World Exploratory Analysis. Ann Surg Oncol. 2025 Oct; 32(10):7215-7227.
-
3D genome organization shapes DNA damage susceptibility to platinum-based drugs. Nucleic Acids Res. 2025 May 22; 53(10).
-
Chemotherapy and the somatic mutation burden of sperm. JCI Insight. 2025 06 23; 10(12).
-
DNA damage causes ATM-dependent heterochromatin loss leading to nuclear softening, blebbing, and rupture. Mol Biol Cell. 2025 Mar 01; 36(3):br6.